Compare Main Street Capital Corporation (MAIN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.07B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Main Street Capital Corporation is far larger — about 2.2× Recursion Pharmaceuticals Inc's market cap, and Main Street Capital Corporation pays a 5.87% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MAIN | RXRX | |
|---|---|---|
Market Cap | $5.07B | $2.31B |
Volume | 685,683 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $64.60 | $6.79 |
52-Week Low | $49.63 | $2.84 |
Typical Hold Time | 88 Days | 22 Days |
Enterprise Value | $7.51B | $1.83B |
Dividend Yield | 5.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with an 80.77% net income margin. Recent news highlights MAIN's status as a top-tier BDC with a well-covered monthly dividend, though some analysts cite valuation concerns amid rising Treasury yields.
Outlook remains cautiously optimistic given MAIN's robust fundamentals and dividend track record, but near-term headwinds include earnings volatility and premium valuation risks. The stock offers income appeal with a 7.9%+ yield, yet investors face pressure from technical weakness and macroeconomic sensitivity.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
